ORAI3 and prostate cancer: Given the extraordinary 2-APB specific electrophysiological profile of hPEC (Figure 3), the low Orai1:Orai3 ratio of ~4 (Figure 1) and Orai3's property to enhance Ca2+ currents upon 2-APB application [44-48] we tested the ability of Orai3 to shape the 2-APB specific electrophysiological profile of ICRAC in the prostate cancer cell line LNCaP as LNCaP are less delicate to patch after transfection than hPEC.